Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest Presentations
May 22, 2023
Press Releases
September 19, 2023
August 10, 2023
Events & Presentations
September 26, 2023 at 10:30 AM EDT
June 15, 2023 at 8:00 AM PDT
June 7, 2023 at 8:30 AM EDT